PBMs and CAA
One of the key provisions of the CAA is the requirement for PBMs to provide more transparency regarding their pricing, compensation and rebate practices. Under the new law, PBMs will be required to disclose information about the amount and type of rebates they receive from drug manufacturers and how they are used. This information will […]